Results 51 to 60 of about 19,563 (105)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections

open access: yes, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and ...
Hung-Jen Tang   +2 more
core   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

open access: yesHealth Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov   +7 more
wiley   +1 more source

Ex vivo characterisation of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactam

open access: yes, 2018
The combination product meropenem/vaborbactam, with activity against KPC-producing carbapenem resistant Enterobacteriaceae, is likely to be used during renal replacement therapy. The aim of this work was to describe the extracorporeal removal (adsorption
Sime, Fekade B.   +10 more
core   +1 more source

NCY‐1 β‐Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica

open access: yesMicrobiologyOpen, Volume 15, Issue 2, April 2026.
This study shows a strong correlation between the β‐lactam susceptibility profile of a clinical isolate of Nocardia cyriacigeorgica and the activity of its β‐lactamase, NCY‐1. Inhibitors of NCY‐1 reduce the minimum inhibitory concentration of amoxicillin.
Julie Couston   +8 more
wiley   +1 more source

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis

open access: yes, 2018
The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant ...
Kelly Peterson   +8 more
core   +1 more source

Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study [PDF]

open access: yes, 2022
Objectives To explore the real-life performance of meropenem/vaborbactam for treating serious KPC-producing Klebsiella pneumoniae infections, including those resistant to ceftazidime/avibactam.
Raffaelli, Francesca   +47 more
core   +1 more source

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

open access: yesMicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li   +4 more
wiley   +1 more source

A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study

open access: yes, 2019
A simple method for the simultaneous quantification of meropenem and the recently approved β-lactamase inhibitor, vaborbactam, in human plasma and renal replacement therapy effluent (RRTE) was developed and validated. This antibiotic combination protects
Sime, Fekade B.   +5 more
core   +1 more source

Resistance to ceftazidime/Avibactam plus meropenem/Vaborbactam when both are used together is achieved in four steps in metallo-β-lactamase-negative klebsiella pneumoniae

open access: yes, 2020
Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella pneumoniae isolates.
Avison, Matthew B   +3 more
core   +1 more source

METHOD DEVELOPMENT AND VALIDATION FOR MEROPENEMAND VABORBACTAM BY RP-HPLC METHOD

open access: yes, 2023
A simple, Accurate, precise method was developed for the simultaneous estimation of the Meropenem and Vaborbactam in Tablet dosage form. Chromatogram was run through Inertsil ODS C185mm (4.6 x 250mm).
D.Vaishnavi, Dr V.Kiran Kumar
core   +1 more source

Home - About - Disclaimer - Privacy